Cost-effectiveness of abiraterone treatment in patients with castration-resistant prostate cancer who previously received docetaxel therapy

<p><strong>Background.</strong> Therapy for metastatic castration-resistant prostate cancer (CRPC) is a serious problem that requires significant public health care expenditures.</p><p><strong>Objective</strong>: to evaluate the cost-effectiveness of abirate...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: A. V. Rudakova, D. O. Meshkov, S. V. Mishugin
Médium: Artigo
Jazyk:Russo
Vydáno: ABV-press 2014-11-01
Edice:Onkourologiâ
Témata:
castration-resistant prostate cancer
chemotherapy
docetaxel
abiraterone
survival
cost effectiveness
On-line přístup:http://oncourology.abvpress.ru/index.php/oncur/article/view/383
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky